人類DNA疫苗市場－全球產業規模、佔有率、趨勢、機會和預測：按給藥途徑、應用、最終用戶、地區和競爭格局分類，2021-2031年

全球人類DNA疫苗市場預計將經歷顯著成長，從2025年的3.7102億美元成長到2031年的5.8128億美元，複合年成長率為7.77%。

這些先進的免疫誘導劑利用重組質體DNA誘導宿主細胞產生抗原，刺激全面的體液和細胞免疫反應。推動市場擴張的關鍵因素包括：DNA疫苗卓越的熱穩定性顯著降低了對低溫運輸物流的依賴，以及質體的快速生產，使得在感染疾病感染疾病期間能夠迅速部署。這些顯著的營運優勢使DNA技術有別於傳統的疫苗接種方法，推動了其應用範圍的擴大，尤其是在腫瘤學和新興感染疾病防治領域。全球傳染病和通用感染疾病暴發負擔的日益加重是主要驅動力，而DNA平台具有快速適應性和擴充性，這對於應對傳統免疫接種無法解決的新威脅和病原體至關重要。例如，世界衛生組織（世衛組織）於2024年10月發布的《世界結核病報告》指出，2023年新增結核病病例達到創紀錄的820萬例，凸顯了對下一代DNA疫苗的迫切需求。同時，DNA疫苗遞送系統的技術進步，例如電穿孔和無針噴射輸液設備，正在克服細胞內攝取和免疫抗原性的傳統障礙。這些創新技術能夠促進質體進入細胞核，在無需侵入性給藥的情況下增強免疫反應。 PharmaJet公司2024年10月的報告證實了這一點，該報告顯示，其無針系統已在感染疾病和腫瘤治療領域的52項臨床試驗中得到應用。這些改進在腫瘤學這一快速發展的領域中尤其重要，因為精準的免疫刺激至關重要。個人化DNA免疫療法的發展正在加速，尤其是在美國癌症協會預測2025年美國新增癌症病例將超過200萬例的情況下。

市場促進因素

全球感染疾病和通用感染疾病疫情負擔日益加重，是推動全球人類DNA疫苗市場發展的主要動力。 DNA平台具有快速適應性和擴充性，在應對新出現的威脅和傳統免疫方法無法應對的流行病原體方面，展現出無可比擬的優勢。這種方法能夠快速設計針對新型病毒標靶的候選疫苗，隨著呼吸道感染和細菌感染疾病在全球捲土重來，這項能力變得愈發重要。世界衛生組織（世衛組織）於2024年10月發布的《2024年全球結核病報告》顯示，2023年全球新增結核病病例約820萬例，創下全球監測以來的最高紀錄。發病率的激增凸顯了對新一代DNA疫苗的迫切需求，這些疫苗能夠有效對抗傳統方法難以應對的複雜病原體。同時，DNA疫苗遞送系統的技術進步正在克服細胞內攝取和免疫抗原性的傳統障礙。電穿孔和無針噴射輸液設備的創新正在提高質體進入細胞核的效率，從而增強免疫反應，並避免了侵入性給藥的不適。據PharmaJet公司在2024年10月世界疫苗大會的新聞稿中稱，其無針注射系統目前已應用於感染疾病和腫瘤開發計畫的52項臨床試驗。這些遞送技術的改進在蓬勃發展的腫瘤學領域尤其重要，因為該領域需要精準的免疫刺激來靶向腫瘤相關抗原。美國癌症協會預測，到2025年，美國將新增超過200萬例癌症病例，將加速利用這些先進遞送平台開發個人化DNA免疫療法。

市場挑戰

人類DNA疫苗廣泛應用的主要障礙在於其難以在人體內產生足夠的免疫抗原性。在許多情況下，需要使用電穿孔等侵入性遞送系統來確保細胞內有效吸收。雖然質體DNA具有熱穩定性，但其透過標準注射方式實現細胞內吸收的效率較低，因此需要專門的設備來遞送電脈衝，這顯著增加了患者的不適感和後勤複雜性。這些操作成本和技術負擔往往超過了其穩定性優勢，使得這些疫苗與更容易使用的競爭疫苗相比，不適合大規模群體免疫接種。因此，這種遞送障礙限制了市場擴張，該技術主要局限於特定治療領域，而非感染疾病預防所需的大規模生產。 2024年底，國際藥品製造商協會聯合會（IFPMA）指出，世界衛生組織指定的50種優先病原體候選疫苗中，大多數都採用了無需額外硬體的成熟遞送方法。這凸顯了依賴侵入性電穿孔設備的 DNA 疫苗在與這些更容易獲得的替代疫苗競爭中獲得顯著市場佔有率的艱難處境。

市場趨勢

市場正經歷兩大關鍵趨勢帶來的重大變革。首先，向微環和線性DNA載體架構的轉變正在革新生產方法，從細菌質體發酵轉向無細胞酶法。這項創新消除了抗生素抗藥性基因，顯著縮短了生產時間，並確保了高純度和安全性，適用於人體給藥。該技術的商業性可行性顯而易見。 2024年7月，Touchlight公司宣布其酵素法dbDNA技術已被應用於客戶產品中，並已獲得三項臨床實驗申請（IND）或臨床試驗申請（CTA）的受理。這使得開發人員能夠避免傳統質體生產過程中遇到的監管和物流瓶頸。其次，個人化新抗原癌症疫苗的出現標誌著精準腫瘤治療的模式轉移。這些疫苗利用基因測序設計質體，誘導針對特定癌症抗原的強效且個人化的T細胞反應，並針對患者特異性的腫瘤突變。 2024年4月，Geneos Therapeutics發布新聞稿稱，其個人化DNA疫苗GNOS-PV02在進行性肝細胞癌患者中取得了30.6%的整體緩解率（ORR），展現了該療法的潛力。這表明，即使在標準療法往往不足以應對的複雜腫瘤領域，該平台也能夠提供有效的免疫療法。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球人類DNA疫苗市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 給藥途徑（肌肉注射、皮下注射、皮內注射、其他）
  • 依應用領域（腫瘤學、結核病學、愛滋病、其他）
  • 依最終用戶（醫院/診所、生技/製藥公司、學術/研究機構、其他）分類
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美人類DNA疫苗市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲人類DNA疫苗市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區人類DNA疫苗市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲人類DNA疫苗市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲人類DNA疫苗市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球人類DNA疫苗市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• BOEHRINGER INGELHEIM GmbH
• ELI-LILLY and Companay
• Gene One Life Science Inc,
• GEOVAX LABS, INC
• Inovio Pharmaceuticals Inc.
• Genexine, Inc.
• VIATRIS INC.
• Takara Holdings Inc.
• ZOETIS INC.
• Zydus Lifesciences Limited

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Human DNA Vaccine Market is projected for substantial growth, expanding from USD 371.02 Million in 2025 to USD 581.28 Million by 2031, demonstrating a CAGR of 7.77%. These advanced immunizing agents leverage genetically engineered plasmid DNA to induce antigen production within host cells, thereby stimulating comprehensive humoral and cellular immune responses. Key drivers for this market expansion include the exceptional thermal stability of DNA vaccines, which significantly reduces the reliance on cold-chain logistics, and the rapid pace of plasmid manufacturing, enabling swift deployment during infectious disease outbreaks. These distinct operational advantages set DNA technology apart from traditional vaccine modalities and are propelling its increasing application, particularly in oncology and against emerging infectious diseases. The escalating global burden of infectious diseases and zoonotic outbreaks serves as a primary catalyst, with DNA platforms offering rapid adaptability and scalability crucial for addressing novel threats and pathogens that elude conventional immunization. For instance, the World Health Organization's October 2024 'Global Tuberculosis Report' highlighted 8.2 million new TB diagnoses in 2023, the highest recorded, underscoring the urgent demand for next-generation DNA vaccines. Concurrently, technological advancements in DNA vaccine delivery systems, such as electroporation and needle-free jet injection devices, are overcoming historical barriers related to cellular uptake and immunogenicity. These innovations enhance plasmid entry into cell nuclei, amplifying the immune response without invasive administration, as evidenced by PharmaJet's October 2024 report on its needle-free systems being utilized in over 52 clinical studies across infectious disease and oncology programs. Such improvements are particularly vital for the expanding oncology segment, where precise immune stimulation is critical, especially with projections from the American Cancer Society of over 2 million new cancer cases in the United States in 2025, fueling the development of personalized DNA immunotherapies.

Market Driver

The escalating global burden of infectious diseases and zoonotic outbreaks serves as a primary catalyst for the Global Human DNA Vaccine Market. DNA platforms offer rapid adaptability and scalability, making them uniquely positioned to address emerging threats and prevalent pathogens that evade traditional immunization methods. This modality allows for the quick design of vaccine candidates against novel viral targets, a capability that is increasingly critical as respiratory and bacterial infections resurge worldwide. According to World Health Organization, October 2024, in the 'Global Tuberculosis Report 2024', approximately 8.2 million people were newly diagnosed with tuberculosis in 2023, the highest number recorded since global monitoring began. This rising incidence underscores the urgent demand for next-generation DNA vaccines capable of providing robust protection against complex pathogens where conventional approaches have historically fallen short. Simultaneously, technological advancements in DNA vaccine delivery systems are overcoming historical barriers related to cellular uptake and immunogenicity. Innovations in electroporation and needle-free jet injection devices are enhancing the efficiency of plasmid entry into cell nuclei, thereby amplifying the immune response without the discomfort of invasive administration. According to PharmaJet, October 2024, in a press release regarding the World Vaccine Congress, its needle-free injection systems are now being utilized in over 52 clinical studies across infectious disease and oncology development programs. These delivery improvements are particularly vital for the expanding oncology segment, where precise immune stimulation is required to target tumor-associated antigens. According to American Cancer Society, in 2025, over 2 million new cancer cases are projected to be diagnosed in the United States, driving the intensified development of personalized DNA immunotherapies utilizing these advanced delivery platforms.

Market Challenge

A primary challenge impeding the broader adoption of human DNA vaccines is the inherent difficulty in achieving sufficient immunogenicity in humans, often necessitating the use of invasive delivery systems like electroporation to ensure adequate cellular uptake. While plasmid DNA offers thermal stability, its poor cellular uptake via standard injection requires specialized devices to deliver electrical pulses, significantly increasing patient discomfort and logistical complexity. This operational cost and technical burden often negate the stability advantages, making these vaccines less viable for widespread mass immunization compared to more user-friendly competitors. Consequently, this delivery barrier restricts the market's expansion, confining the technology largely to niche therapeutic areas rather than high-volume infectious disease prevention. The International Federation of Pharmaceutical Manufacturers & Associations noted in late 2024 that a majority of 50 competing vaccine candidates for WHO priority pathogens utilized established delivery modalities that do not require additional hardware, highlighting the struggle for DNA vaccines tied to invasive electroporation equipment to capture significant market share against these more accessible alternatives.

Market Trends

The market is undergoing significant transformation through two key trends. Firstly, the transition to Minicircle and Linear DNA Vector Architectures is revolutionizing production by shifting from bacterial plasmid fermentation to cell-free, enzymatic methods. This innovation eliminates antibiotic resistance genes, drastically accelerates manufacturing timelines, and ensures higher purity and safety for human administration. The commercial viability of this technology is evident, with Touchlight reporting in July 2024 that its enzymatic dbDNA technology has been implemented in client products with three accepted Investigational New Drug (IND) or Clinical Trial Applications (CTAs), allowing developers to bypass regulatory and logistical bottlenecks of conventional plasmid manufacturing. Secondly, the emergence of Personalized Neoantigen Cancer Vaccines represents a paradigm shift toward precision oncology therapeutics. These vaccines are designed to target patient-specific tumor mutations, utilizing genomic sequencing to engineer plasmids that induce a potent, individualized T-cell response against unique cancer antigens. Geneos Therapeutics, in an April 2024 press release, substantiated this therapeutic potential by reporting a 30.6% Overall Response Rate (ORR) with its personalized DNA vaccine GNOS-PV02 in patients with advanced hepatocellular carcinoma, showcasing the platform's capacity to deliver effective immunotherapies in complex oncology settings where standard treatments frequently fall short.

Key Market Players

• BOEHRINGER INGELHEIM GmbH
• ELI-LILLY and Companay
• Gene One Life Science Inc,
• GEOVAX LABS, INC
• Inovio Pharmaceuticals Inc.
• Genexine, Inc.
• VIATRIS INC.
• Takara Holdings Inc.
• ZOETIS INC.
• Zydus Lifesciences Limited

Report Scope

In this report, the Global Human DNA Vaccine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Human DNA Vaccine Market, By Route of Administration

• Intramuscular
• Subcutaneous
• Intradermal
• Others

Human DNA Vaccine Market, By Application

• Oncology
• Tuberculosis
• HIV
• Others

Human DNA Vaccine Market, By End User

• Hospitals & Clinics
• Biotechnology & Pharmaceutical Companies
• Academic & Research Institutions
• Others

Human DNA Vaccine Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Human DNA Vaccine Market.

Available Customizations:

Global Human DNA Vaccine Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Human DNA Vaccine Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Route of Administration (Intramuscular, Subcutaneous, Intradermal, Others)
  • 5.2.2. By Application (Oncology, Tuberculosis, HIV, Others)
  • 5.2.3. By End User (Hospitals & Clinics, Biotechnology & Pharmaceutical Companies, Academic & Research Institutions, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Human DNA Vaccine Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Route of Administration
  • 6.2.2. By Application
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Human DNA Vaccine Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Route of Administration
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Human DNA Vaccine Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Route of Administration
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Human DNA Vaccine Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Route of Administration
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End User

7. Europe Human DNA Vaccine Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Route of Administration
  • 7.2.2. By Application
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Human DNA Vaccine Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Route of Administration
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End User
  • 7.3.2. France Human DNA Vaccine Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Route of Administration
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Human DNA Vaccine Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Route of Administration
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Human DNA Vaccine Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Route of Administration
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Human DNA Vaccine Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Route of Administration
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End User

8. Asia Pacific Human DNA Vaccine Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Route of Administration
  • 8.2.2. By Application
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Human DNA Vaccine Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Route of Administration
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End User
  • 8.3.2. India Human DNA Vaccine Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Route of Administration
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Human DNA Vaccine Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Route of Administration
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Human DNA Vaccine Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Route of Administration
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Human DNA Vaccine Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Route of Administration
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End User

9. Middle East & Africa Human DNA Vaccine Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Route of Administration
  • 9.2.2. By Application
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Human DNA Vaccine Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Route of Administration
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Human DNA Vaccine Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Route of Administration
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Human DNA Vaccine Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Route of Administration
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End User

10. South America Human DNA Vaccine Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Route of Administration
  • 10.2.2. By Application
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Human DNA Vaccine Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Route of Administration
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Human DNA Vaccine Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Route of Administration
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Human DNA Vaccine Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Route of Administration
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Human DNA Vaccine Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. BOEHRINGER INGELHEIM GmbH
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. ELI-LILLY and Companay
• 15.3. Gene One Life Science Inc,
• 15.4. GEOVAX LABS, INC
• 15.5. Inovio Pharmaceuticals Inc.
• 15.6. Genexine, Inc.
• 15.7. VIATRIS INC.
• 15.8. Takara Holdings Inc.
• 15.9. ZOETIS INC.
• 15.10. Zydus Lifesciences Limited

16. Strategic Recommendations

17. About Us & Disclaimer